Abstract Submission Guidelines

These guidelines are only applicable to non-Japanese researchers living outside of Japan who would like to submit abstracts.
Non-Japanese researchers residing in Japan or who belong to a Japanese institution should become members of the Japanese Society of Anti-Aging Medicine and submit their abstract on our Japanese site.

Current members of the Japanese Society of Anti-Aging Medicine should also submit their abstract on our Japanese site.
Submissions are accepted only via email to the conference secretariat (17jaam@mediproduce.com) by filling out the Abstract Submission Form attached at the bottom of this page.

Submission Dates and Deadline

Presentation Style

Categories

Abstract Submission Content

1. It is the presenter's responsibility to confirm the content of the abstract submission, including its abstract topic, presenter name, abstract body and logic.
2. Please note that you will be requested to rewrite your abstract if any of the following apply:
   
   1. Abstracts deemed to require the approval of the ethics committee or informed consent that do not have ethics committee approval or informed consent stated in the abstract.
   2. Abstracts that are deemed to have logical problems.
   3. Abstracts that are strongly suspected to contain corporate or institutional advertising.
   4. Abstracts deemed to have problems with protecting patients' personal information.
   5. Abstracts with weak scientific and academic significance
3. Please note the following guidelines pertaining to patient and subject privacy when submitting your abstract.
   
   1. Do not include specific names, patient numbers, initials, or nicknames that can be used to identify the patient or subject.
   2. Dates can be included if it is determined that they cannot be used to determine a specific person.
   3. If the patient or subject is under diagnosis or therapy at another medical institution, do not include the name of the institution or its location.
   4. If the patient or subject can be identified by verifying information such date of surgery or hospitalization, age should be indicated as follows (excluding those 18 years or younger):
      Ex. 40-44 years old > early forties; 45-49 years old > late forties.
4. The first author should be the presenter. It is possible to include a maximum of 20 authors (including the first author) and 10 author affiliations (including that of the first author) in your submission.
5. The abstract title character limit is 120 characters or less. The abstract body character limit is 1,700 characters; if diagrams are included, the character limit is 1,138 characters (half-width). Please note that abstracts over the character length cannot be processed for submission. In addition, we recommend creating the abstract body separately and copy-pasting the text to the abstract body field.

Conflict of Interest (COI)

1. Applicability
   
   1. All authors and presenters, including members and non-members, who are presenting or speaking at a lecture or seminar at the 17th JAAM meeting, or at study groups, trainings, and seminars organized by special interest or regional groups are required to disclose their COI in their abstract submission, detailing their financial relations with corporations involved in medical research or for-profit organizations.
   2. It is up to the submitter to judge whether to disclose COI. The 17th JAAM Secretariat is unable to answer questions related to COI judgment. However, please direct questions pertaining to "Japanese Society of Anti-Aging Medicine COI Committee" to the JAAM Secretariat below.
      
      Secretariat of the Japanese Society of Anti-Aging Medicine
      Phone: +81-3-6402-2600　Email: coi@anti-aging.gr.jp
2. Personal Disclosure
   

   It is the personal responsibility of the submitter to disclose if there is conflict of interest related to the abstract to be presented. Abstracts that do not have any conflict of interest are not required to make a disclosure. It is mandatory to select whether the abstract has COI in the Abstract Submission Form. During the submission process, COI can only be indicated either as YES/NONE. COI is based on the following.

   *Note:

   Please disclose any conflicting interests with corporations, organizations or groups over the past (1) year, counting backwards from the date of submission.

   1. Employment/Leadership position/Advisory role: 1,000,000 yen or more annually from one commercial entity
   2. Stock ownership or options: Profit of 1,000,000 yen or more annually from the stock of one company or ownership of 5% or more of total shares of one company
   3. Patent royalties/licensing fees: 1,000,000 yen or more per one royalty/licensing fee annually
   4. Honoraria (e.g. lecture fees): 1,000,000 yen or more annually from one commercial entity
   5. Manuscript fees: 1,000,000 yen or more annually from one commercial entity
   6. Research funding: 2,000,000 yen or more annual payment to departments (department, field, or laboratory) who share research expenses from the same commercial entity.
   7. Subsidies or Donations: 2,000,000 yen or more annual payment to departments (department, field, or laboratory) who share subsidies or donations from the same commercial entity.
   8. Endowed departments by commercial entities: If any of the authors belongs to an endowed department sponsored by any commercial entity
   9. Travel fees, gifts, and others (except for research, training, education and treatment): 50,000 yen or more annually from one commercial entity
3. On-site disclose on slides and posters
   
   1. COI disclosure on slides and posters should be indicated on the first slide (or after the introductory slide with the title and author names) for slide presentations using the format 1-A, or the prescribed format 1-B at the bottom for posters.

Notification of Receipt of Abstracts

For registration confirmation, notification will be sent to the registered email address. If you do not receive notification at the registered email address within 7 days, please inform the conference secretariat.

Acceptance or Rejection Notification of Abstract

For submissions (general presentations), notification of acceptance or rejection will be sent to the registered email address around end of March 2017 (tentative). Abstract acceptance, schedules, and other details will be determined at the discretion of the conference chair.

For inquiries regarding abstract submission, contact:

Congress Secretariat (MediProduce, Inc.)
2-26-35 8F, Minamiaoyama, Minato-ku, Tokyo 107-0062 Japan
Phone: +81-3-5775-2075　Fax: +81-3-5775-2076
Email: 17jaam@mediproduce.com

For COI disclosure inquiries, contact:

Secretariat of the Japanese Society of Anti-Aging Medicine
Phone: +81-03-5775-2075　Email: coi@anti-aging.gr.jp